Related Experiment Video
Updated: Jul 9, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Toxic warhead-armed antibody for targeted treatment of glioblastoma
Jingjing Xi1, Kai Liu1, Zhaolei Peng1
1State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Abstract:
Glioblastoma is a fatal intracranial tumor with a poor prognosis, exhibiting uninterrupted malignant progression, widespread invasion throughout the brain leading to the destruction of normal brain tissue and inevitable death. Monoclonal antibodies alone or conjugated with cytotoxic payloads to treat patients with different solid tumors showed effective. This treatment strategy is being explored for patients with glioblastoma (GBM) to obtain meaningful clinical responses and offer new drug options for the treatment of this devastating disease. In this review, we summarize clinical data (from pubmed.gov database and clinicaltrial.gov database) on the efficacy and toxicity of naked antibodies and antibody-drug conjugates (ADCs) against multiple targets on GBM, elucidate the mechanisms that ADCs act at the site of GBM lesions. Finally, we discuss the potential strategies for ADC therapies currently used to treat GBM patients.
Insights
Monoclonal antibodies and antibody-drug conjugates (ADCs) show promise for treating glioblastoma (GBM). This review explores their efficacy, toxicity, and mechanisms against this aggressive brain tumor.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Biology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis.
- Current treatments have limited efficacy, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review clinical data on naked antibodies and antibody-drug conjugates (ADCs) for glioblastoma treatment.
- To elucidate the mechanisms of action of ADCs in GBM lesions.
- To discuss current and potential ADC therapy strategies for GBM.
Main Methods:
- Systematic review of clinical data from PubMed and ClinicalTrials.gov.
- Analysis of efficacy and toxicity of antibody-based therapies.
- Examination of ADC mechanisms against GBM targets.
Main Results:
- Antibodies and ADCs are being explored for GBM, showing potential for clinical responses.
- Data on efficacy and toxicity of various antibody therapies against GBM targets are summarized.
- Mechanisms of ADC action at GBM lesion sites are elucidated.
Conclusions:
- Antibody-based therapies, including ADCs, represent a promising avenue for glioblastoma treatment.
- Further research into ADC mechanisms and therapeutic strategies is crucial for improving patient outcomes.
- ADCs offer new drug options for this devastating disease.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy